Telatinib sustained-release implantation agent for treating solid tumors

The invention relates to a teratinib sustained release implant for treating solid tumors, which is characterized in that the sustained release implant contains teratinib and sustained-release excipient of effective anticancer amount and certain amount of sustained release regulator. The solid tumors comprise lung cancer, esophageal cancer, carcinoma ventriculi, liver cancer, mammary cancer, oophoroma, prostatic carcinoma, carcinoma of urinary bladder and colorectal cancer. The sustained-release excipient is mainly one of or the combination of copolymer of glycollic acid and glycolic acid, Polifeprosan, poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co-propyl phosphate), and the teratinib is slowly released into local tumor during the degradation and absorption process, therefore the invention not only obviously reduces toxic reaction of the whole body, but also maintains effective drug concentration at the local tumor. The sustained release implant is arranged in the local tumor, which not only reduces